Ectonucleotidase Modulation of Lymphocyte Function in Gut and Liver

Area of Science:

• Immunology
• Biochemistry
• Molecular Biology

Background:

• Immune system imbalance between regulatory and effector T lymphocytes drives chronic inflammatory and autoimmune disorders.
• The CD39 ectonucleotidase enzyme regulates T-cell balance by hydrolyzing ATP/ADP to AMP, which is further converted to adenosine.
• Adenosine generated by CD39 influences T-cell function, suppressing regulatory T cells (Tregs) and enhancing regulatory properties of pathogenic Th17 cells.

Purpose of the Study:

• To review the role of CD39 in immune regulation and its impact on inflammatory signaling pathways.
• To discuss the distribution and regulatory mechanisms of CD39.
• To explore innovative therapeutic strategies targeting CD39 for chronic inflammatory and autoimmune diseases.

Main Methods:

• Review of existing literature on CD39 function, distribution, and therapeutic potential.
• Analysis of CD39's role in T-cell suppression and regulatory signaling.
• Examination of therapeutic strategies involving soluble ADPases and CD39 inhibitory signals.

Main Results:

• CD39 plays a pivotal role in maintaining immune tolerance by regulating the balance between effector and regulatory T cells.
• Adenosine production mediated by CD39 impacts Treg suppression and confers regulatory functions to Th17 cells.
• Restoring CD39 levels and function presents significant translational and clinical implications for treating chronic inflammatory conditions.

Conclusions:

• CD39 is a key regulator of immune responses and a potential therapeutic target for chronic inflammatory and autoimmune diseases.
• Targeting CD39 offers a novel treatment approach for conditions such as Crohn's disease and autoimmune hepatitis.
• Restoration of CD39 function holds promise for improving immunotolerance and managing inflammatory disorders.